Heat shock protein as a targeting agent for...

Details Heat shock protein as a targeting agent for... Heat shock protein as a targeting agent for...

2004-08-13

2009-08-18

Jones, D L (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001810, C424S001850, C424S001890

Reexamination Certificate

active

07575738

ABSTRACT:
The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for the diagnosis and monitoring of diseases as well as means for internalizing signaling moieties and therapeutics.

REFERENCES:
patent: 4752141 (1988-06-01), Sun et al.
patent: 4986671 (1991-01-01), Sun et al.
patent: 5175343 (1992-12-01), Fritzberg et al.
patent: 5217456 (1993-06-01), Narciso, Jr.
patent: 5275594 (1994-01-01), Baker et al.
patent: WO 02 067761 (2002-06-01), None
Lee et al (1996), Plant Physiology, vol. 110, No. 1, pp. 241-248.
Mansfield et al (1987), Plant Physiology, vol. 84, No. 4, pp. 1007-1017.
Perdew (1988), Journal of Biological Chemistry, vol. 263, No. 27, pp. 13802-13805.
Hernando et al (1997), European Journal of Biochemistry, vol. 243, Nos. 1/2, pp. 460-467.
Arthur Agatston, M.D., et al., “Quantification of Coronary Artery Calcium Using Ultrafast Computed Tomography”,J. Am. Coll. Cardiol. 1990, 15, pp. 827-832.
Edwin L. Alderman, M.D., et al., “Five-year Angiographic Follow-up of Factors Associated With Progression of Coronary Artery Disease in the Coronary Artery Surgery Study (CASS)”,J. Am. Coll. Cardiol. 1993, 22, pp. 1141-1154.
John A. Ambrose, M.D., et al., “Angiographic Progression of Coronary Artery Disease and the Development of Myocardial Infarction”,J. Am. Coll. Cardiol. 1988, 12, pp. 56-62.
William C. Little, “Can Coronary Angiography Predict The Site of Subsequent Myocardial Infarction in Patients With Mild-to-Moderate Coronary Artery Disease?”,Circulation, 1988, 78, pp. 1157-1166.
J.A. Ambrose, M.D., In: Fuster, V. (Ed.).Syndromes of Atherosclerosis: correlations of clinical imaging and pathology. Armonk, NY: Futura Publishing Company, Inc., 1996, pp. 105-122.
C.R. Becker, et al., “Visualization and Quantification of Coronary Calcifications with Electron Beam and Spiral Computed Tomography”,Eur. Radiol. 2000, 10, pp. 629-635.
B.H. Brundage, M.D., In: Fuster, V. (Ed.).Syndromes of Atherosclerosis: correlations of clinical imaging and pathology. Armonk, NY: Futura Publishing Company, Inc., 1996, pp. 417-427.
M.J. Budoff, M.D., et al., “Rates of Progression of Coronary Calcium by Electron Beam Tomography”,Am. J. Cardiol, 2000, 86, pp. 8-11.
C. Carrington, “Could Coronary Calcium Sceening Prevent This?”,Diagnostic Imaging, 2000, (April), pp. 48-53.
T.M. Doherty, et al., “Coronary Calcium: The good, the bad, and the uncertain”,Am. Heart J. 1999, 137, pp. 806-814.
M.D. Cerqueira, “Current Status of Radionuclide Tracer Imaging of Thrombi and Antheroma”,Seminars Nucl. Med. 1999, 29, pp. 339-351.
R.E. Dinsmore, S.M. Rivitz. In: Fuster, V. (Ed.).Syndromes of Atherosclerosis: correlations of clinical imaging and pathology, Armonk, NY: Futura Publishing Company, Inc., 1996, pp. 277-289.
M. Doyle, G. Pohost. In: Fuster, V. (Ed.).Syndromes of Atherosclerosis: correlations of clinical imaging and pathology. Armonk, NY: Futura Publishing Company, Inc., 1996, pp. 313-332.
R. Erbel, et al., “Electron-Beam Computed Tomography for Detection of Early Signs of Coronary Arteriosclerosis”,Eur. Heart J. 2000, 21, 720-732.
A. Farb, et al., “Sudden Coronary Death: Frequency of Active Coronary Lesions, Inactive Coronary Lesions, and Myocardial Infarction”,Circulation, 1995, 92, pp. 1701-1709.
Z.S. Galis, et al., Macrophage Foam Cells From Experimental Atheroma Constitutively Produce Matrix-Degrading Proteinases,Pro. Acad. Sci. USA, 1995, 92, pp. 402-406.
M. Goyen et al., “MR-Angiography: the role of contrast agents”,Eur. J. Radio. 2000, 34, 247-256.
T.M. Grist, M.D., P.A. Turski, M.D. In: Fuster, V. (Ed.).Syndromes of Atherosclerosis: correlations of clinical imaging and pathology. Armonk, NY: Futura Publishing Company, Inc., 1996, pp. 333-362.
H. Ikeda et al., “Increased Soluble Form of P-Selectin in Patients With Unstable Angina”,Am. J. Cardiol, 1990, 65, 1693-1696.
L. Iuliano, et al., “Preparation and Biodistribution of 99m technetium Labelled Oxidized LDL in man”,Atherosclerosis, 1996, 126, pp. 131-141.
W.R. Janowitz, M.D., et al., “Differences in Prevalence and Extent of Coronary Artery Calcium Detected by Ultrafast Computed Tomographay in Asymptomatic Men and Women”,Am. J. Cardiol., 1993, 72, pp. 247-254.
J.C. Kaski, MD, et al., “Rapid Angiographic Progression of Coronary Artery Disease in Patents with Angina Pectoris”,Circulation, 1995, 92, pp. 2058-2065.
M.V. Knopp, M.D., et al., “Contrast Agents for MRA: Future Directions”,J. Magn. Reson, Imaging, 1999, 10, pp. 314-316.
D.N. Ku, et al., “Pulsatile Flow and Atherosclerosis in the Human Carotid Bifurcation”,Atherosclerosis, 1985, 5, pp. 292-302.
M. Marmion, E. Deutsch. “Tracers and Contrast Agents in Cardiovascular Imaging: present and future”,J. Nucl. Biol. Med., 1996, 40, pp. 121-131.
A. Mazzone, M.D., et al., “Increased Expression of Neutrophil and Monocyte Adhesion Molecules in Unstable Coronary Artery Disease”,Circulation, 19963, August, 88, No. 2, pp. 358-363.
E.R. McVeigh, “MRI of Myocardial Function: Motion Tracking Techniques”,Magn. Reson. Imaging1996, 14, No. 2, pp. 137-150.
G.H. Glover, Ph.D., R.J. Herfkens, M.D., “Research Directions in MR Imaging”,J. Radiology, 1998, 207, No. 2, pp. 289-295.
J.F.M. Meaney, et al., “Pulmonary Magnetic Resonance Angiography”,J. Magn. Reson. Imaging, 1999, 10, pp. 326-338.
J. Narula, M.D., et al., “Strategic Targeting of Atherosclerotic Lesions”,J. Nucl. Cardiol, 1999, 6, pp. 81-90.
J. Narula, M.D., “POPE: Predicting Outcome By Plaque Evaluation”,Nucl. Med. Commun. 2000, 21, pp. 601-608.
M.R. Patel, M.D., et al., “Preoperative Assessment of The Carotid Bifurcation”,Stroke, 1995, 26, 1753-1758.
J.F. Polak, M.D., “Focus on Imaging at the American Heart Association Annual Meeting”, Radiology, 2000, 216, pp. 323-324.
R. Ross, “The Pathogenesis of Atherosclerosis: a perspective for the 1990s”, Nature, 1993, 362, pp. 801-909.
J.A. Rumberger, Ph.D., M.D., “Electron Beam CT and Coronary Calcium Score”, Circulation 1998, 97, pp. 2095-2097.
A. Schmermund, M.D., et al., “Usefulness of Topography of Coronary Calcium by Electron-Beam Computed Tomography in Predicting the Natural History of Coronary Atherosclerosis”,Am. J. Cardio. 2000, 86, pp. 127-132.
A. Shaish, et al., “Imaging of Aortic Atherosclerotic Lesions by 125 I-LDL, 125 I-Oxidized-LDL, 125 I-HDL and 125 I-BSA”,Pathobiology, 2001, 69, pp. 225-229.
D. Steinberg, “Low Density Lipoprotein Oxidation and its Pathobiological Significance”,J. Biol. Chem, 1997, 272, pp. 29063-29066.
J-F Toussaint, M.D., et al., “T2-Weighted Contrast for NMR Characterization of Human Atherosclerosis”,Anterioscler Throb Vasc Biol, 1995, 15, No. 10, pp. 1533-1542.
J-F Toussaint, M.D., et al., “Magnetic Resonance Images Lipid, Fibrous, Calcified, Hemorrhagic, and Thrombotic Components of Human Atherosclerosis In Vivo”,Circulation1996, 94, pp. 932-938.
S. Tsimikas, et al., “In Vivo Uptake of Radiolabeled MDA2, an Oxidation-Specific Monoclonal Antibody, Provides an Acc. Meas. of Atherosclerotic Lesions Rich in Oxidized LDL and Is Highly Sensitive to Their Regression”,Anterioscler Throb Vasc Biol, 2000, 689-697.
S. Vallabhajosula, V.J. Fuster, “Atherosclerosis: Imaging Techniques and the Evolving Role of Muclear Medicine”,J. Nucl. Med. 1997, 38, pp. 1788-1796.
J. Weinberger, M.D., et al., “Morphologic and Dymanic changes of Atherosclerotic Plaque at the Carotid Arthery Bifurcation: Sequential Imaging by Real Time B-Mode Ultrasonography&#

Affiliated with

Also associated with

Rating

Heat shock protein as a targeting agent for... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heat shock protein as a targeting agent for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heat shock protein as a targeting agent for... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4085538